Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Abstract

This follow-up study measures the antibody response following the second dose of SARS-CoV-2 mRNA vaccine in recipients of solid organ transplants.

Conflict of interest statement

Conflict of Interest Disclosures: Dr Werbel reported receiving grants from the American Society of Transplantation Research Network Clinical Science Fellowship Grant. Dr Avery reported receiving grants from Aicuris, Astellas, Chimerix, Merck, Oxford Immunotec, Qiagen, and Takeda/Shire. Dr Segev reported serving as a consultant to and receiving honoraria for speaking from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallincrodt, and Thermo Fisher Scientific. No other disclosures were reported.

Figures

Figure.. Antibody Levels of Study Participants After 2-Dose Series of SARS-CoV-2 mRNA Vaccine

A, Roche Elecsys anti–SARS-CoV-2 S enzyme immunoassay (n = 470) tests for total antibody against the receptor-binding domain of the SARS-CoV-2 spike protein. The manufacturer cutoff for detectable antibody is 0.80 U/mL (shown as a horizontal orange line). The lowest value reported by the assay is 250. B, EUROIMMUN enzyme immunoassay (n = 188) tests for IgG to the S1 domain of SARS-CoV-2 spike protein. The manufacturer cutoff for detectable antibody is 1.1 arbitrary units (shown as a horizontal red line). The lines beginning at dose 1 reflect the antibody trajectory of participants who had detectable antibody after dose 1. Orange dots represent the antibody levels of participants who had undetectable antibody after dose 1.